Officer sold ~$439K of Vertex Pharmaceuticals
Scheduled in advanceLoading…
Traded Mar 4, 2026 · Filed Mar 6, 2026
Vertex Pharmaceuticals's Chief Commercial Officer sold $1.16M of Vertex Pharmaceuticals shares. It was planned long ago, so it says very little.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$1,158,306
Shares × reported transaction price
20 days after results of Feb 12, 2026, 61 days before results of May 4, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $477.89 on Mar 4, 2026, 30% above its 52-week low and 7% below its high, after an 8% rise over the previous 30 trading days
52-week range $366.54 (Aug 8, 2025) to $513.76 (Mar 17, 2025), 76% of the way up, from 251 adjusted closes. 30 trading days earlier: $442.08 on Jan 20, 2026. Describes the past only, not a forecast
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
FDA approved Alyftrek on Mar 27, 2026, 23 days after this trade.
New use approved (efficacy supplement). Active ingredient: Deutivacaftor, Tezacaftor, Vanzacaftor Calcium. From openFDA. Dates only; no link between the two is implied
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +1.1% | -1.4% | +2.5% |
| 30 days | -3.7% | -0.3% | -3.4% |
| 90 days | -3.9% | +9.0% | -12.9% |
| 180 days | +14.8% | +12.9% | +1.8% |
Past results only. Not a forecast.
Officer sold ~$439K of Vertex Pharmaceuticals
Scheduled in advanceOfficer sold ~$1.05M of Vertex Pharmaceuticals
Scheduled in advanceOfficer sold ~$1.12M of Vertex Pharmaceuticals
Scheduled in advance